GSK invests $100 million to expand long-term vaccine manufacturing capabilities in Hamilton, MT
Friday, May 10, 2019
- Site expansion will boost vaccine production capacity
- Creating new temporary construction and contracting jobs; and new permanent GSK positions
PHILADELPHIA -- GSK announced $100 million of new investment in its manufacturing site in Hamilton, Montana to expand the production capacity of key components of the adjuvant system used in several of GSK's vaccines, including SHINGRIX, which was approved by the US Food and Drug Administration in October 2017.
For more than 20 years, GSK has been innovating in adjuvant systems and has developed vaccines to help prevent malaria and shingles that utilize adjuvant systems to help achieve a stronger immune response.